Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Arthritis Rheumatol. 2016 Jul;68(7):1711–1720. doi: 10.1002/art.39614

Table 2.

Cumulative incidence of study outcomes by time period

Outcome All Time Period
P-value for trend
85–89 90–94 95–99 00–04 05–09
ESRD-free survival 1-year 75% 73% 72% 66% 82% 82% 0.02
3-year 61% 51% 57% 53% 69% 72% < 0.001
5-year 54% 39% 53% 40% 68% 70% < 0.001

Patient survival 1-year 91% 89% 89% 89% 93% 90% 0.36
3-year 81% 74% 84% 73% 87% 83% 0.15
5-year 72% 64% 71% 58% 84% 83% < 0.001

Renal survival 1-year 80% 77% 77% 70% 86% 89% 0.005
3-year 69% 60% 61% 60% 76% 84% < 0.001
5-year 65% 51% 61% 53% 76% 82% < 0.001

Relapse 1-year 11% 5% 7% 12% 14% 15% 0.008
3-year 29% 22% 25% 28% 28% 40% 0.01
5-year 35% 28% 27% 33% 30% 57% < 0.001

ESRD, end-stage renal disease